Related Experiment Video

Updated: Aug 10, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Early drug safety evaluation: biomarkers, signatures, and fingerprints

Ruth Roberts1, Kelvin Cain, Beth Coyle

  • 1Aventis Pharma, Drug Safety Evaluation, Centre de Recherche de Paris, Paris, France. ruth.roberts@aventis.com

Drug Metabolism Reviews
|January 7, 2004
PubMed

Insights

Identifying the cause of target organ toxicity in animal drug safety studies is crucial. New technologies like toxicogenomics and proteomics help determine the mechanism of action and human relevance of observed toxicities.

Area of Science:

  • Drug safety evaluation
  • Toxicology
  • Pharmacology

Background:

  • Target organ toxicity in animal models presents challenges in drug safety evaluation.
  • Determining the mechanism of action (MOA) and human relevance of toxicity is essential.
  • Traditional methods rely on pathology and prior knowledge, which may be insufficient.

Purpose of the Study:

  • To explore the utility of novel technologies in elucidating the MOA of target organ toxicity.
  • To investigate how gene expression and protein profiles can inform toxicity assessments.
  • To differentiate toxic pathways from pharmacologically active pathways.

Main Methods:

  • Utilizing toxicogenomics to generate gene expression profiles of toxicity.
  • Employing proteomic analysis to compare protein profiles at toxic versus efficacious doses.
  • Comparing toxicogenomic profiles with reference compounds and other drug candidates.

Main Results:

  • Toxicogenomics provides gene expression profiles that can be compared to identify toxicity patterns.
  • Proteomic analysis at different doses offers insights into the MOA of toxicity.
  • These approaches can help distinguish toxic response pathways from those related to pharmacological activity.

Conclusions:

  • New technologies like toxicogenomics and proteomics offer inductive approaches to investigate drug-induced toxicity.
  • These methods can generate novel research leads when traditional methods are inconclusive.
  • Understanding the MOA and human relevance of toxicity is critical for drug development.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...